Fundz

Silexion Therapeutics reported raising $3.6 Million in an initial SEC Form D filing, from an offering of $3.6 Million

PUBLIC · SLXNAug 11, 2025

Amount Raised

$3.6 Million

$3.6 Million sold, per SEC Form D (first sale Aug 1, 2025)

Round Type

Venture

IsraelBiotechnologyHealth CareTherapeuticsPharmaceutical

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Silexion Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Alchemab Therapeutics raised an undisclosed amount (Series A) on September 9, 2025.
  • Os Therapies raised $3.8M on September 2, 2025.
  • TNF Pharmaceuticals raised $7M on September 2, 2025.
  • Retension Pharmaceuticals raised $15M (Series B) on August 6, 2025.
  • BioSapien raised $8M (Pre-Series A) on July 7, 2025.
  • Pelthos Therapeutics raised $50M on July 1, 2025.

Who to call at Silexion Therapeutics, and when

A new round usually means Silexion Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Silexion Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Silexion Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Silexion Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Silexion Therapeutics

Location

12 Abba Hillel Road

Israel

About

Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Silexion Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Silexion Therapeutics's next move

See what Strategic adds

Silexion Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.